Evidence mapPaperPMID 34911405Full record

ArticleMedical decision making : an international journal of the Society for Medical Decision Making2022

Exploring Structural Uncertainty and Impact of Health State Utility Values on Lifetime Outcomes in Diabetes Economic Simulation Models: Findings from the Ninth Mount Hood Diabetes Quality-of-Life Challenge.

Michelle Tew, Michael Willis, Christian Asseburg, Hayley Bennett, Alan Brennan, Talitha Feenstra, James Gahn, Alastair Gray, Laura Heathcote, William H Herman and 23 more

Abstract read
In one paragraph

Article in Medical decision making : an international journal of the Society for Medical Decision Making, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 2 pooled it
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Impact of Structural Differences on the Modeled Cost-Effectiveness of Noninvasive Prenatal Testing.Medical decision making : an international journal of the Society for Medical Decision Making · 2024
    Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

33 authors.

Michelle TewCentre for Health Policy, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, Victoria, Australia.ORCID 0000-0003-3009-8056
Michael WillisThe Swedish Institute for Health Economics, Lund, Sweden.
Christian AsseburgESiOR Oy, Kuopio, Finland.ORCID 0000-0001-7196-3363
Hayley BennettHealth Economics and Outcomes Research Ltd, Cardiff, UK.
Alan BrennanSchool of Health and Related Research, University of Sheffield, Sheffield, UK.
Talitha FeenstraGroningen University, Faculty of Science and Engineering, GRIP, Groningen, The Netherlands.
James GahnMedical Decision Modeling Inc., Indianapolis, IN, USA.
Alastair GrayHealth Economics Research Centre, Nuffield Department of Population Health, University of Oxford, Oxford, UK.
Laura HeathcoteSchool of Health and Related Research, University of Sheffield, Sheffield, UK.
William H HermanDepartment of Internal Medicine, University of Michigan, Ann Arbor, MI, USA.
Deanna IsamanDepartment of Biostatistics, University of Michigan, Ann Arbor, MI, USA.
Shihchen KuoDepartment of Internal Medicine, University of Michigan, Ann Arbor, MI, USA.
Mark LamotteGlobal Health Economics and Outcomes Research, Real World Solutions, IQVIA, Zaventem, Belgium.
José LealHealth Economics Research Centre, Nuffield Department of Population Health, University of Oxford, Oxford, UK.
Phil McEwanHealth Economics and Outcomes Research Ltd, Cardiff, UK.
Andreas NilssonThe Swedish Institute for Health Economics, Lund, Sweden.
Andrew J PalmerCentre for Health Policy, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, Victoria, Australia.
Rishi PatelHealth Economics Research Centre, Nuffield Department of Population Health, University of Oxford, Oxford, UK.
Daniel PollardSchool of Health and Related Research, University of Sheffield, Sheffield, UK.
Mafalda RamosGlobal Health Economics and Outcomes Research, Real World Solutions, IQVIA, Porto Salvo, Portugal.
Fabian SailerGECKO Institute for Medicine, Informatics and Economics, Heilbronn University, Heilbronn, Germany.
Wendelin SchrammGECKO Institute for Medicine, Informatics and Economics, Heilbronn University, Heilbronn, Germany.
Hui ShaoDepartment of Pharmaceutical Outcomes and Policy. University of Florida College of Pharmacy. Gainesville, FL, USA.
Lizheng ShiDepartment of Health Policy and Management; Tulane University School of Public Health and Tropical Medicine.
Lei SiMenzies Institute for Medical Research, The University of Tasmania, Hobart, Tasmania, Australia.
Harry J SmolenMedical Decision Modeling Inc., Indianapolis, IN, USA.
Chloe ThomasSchool of Health and Related Research, University of Sheffield, Sheffield, UK.
An Tran-DuyCentre for Health Policy, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, Victoria, Australia.ORCID 0000-0003-0224-2858
Chunting YangDepartment of Biostatistics, University of Michigan, Ann Arbor, MI, USA.
Wen YeDepartment of Biostatistics, University of Michigan, Ann Arbor, MI, USA.
Xueting YuMedical Decision Modeling Inc., Indianapolis, IN, USA.
Ping ZhangDivision of Diabetes Translation, Centres for Disease Control and Prevention, Atlanta, GA, USA.
Philip ClarkeCentre for Health Policy, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, Victoria, Australia.

Funding

Pilot and Feasibility ProgramP30DK020572 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · 2022 to 2025
$4.9M
Pilot and Feasibility ProgramP30DK092926 · UNIVERSITY OF MICHIGAN AT ANN ARBOR · 2025 to 2025
$779k
NIDDK NIH HHS P30 DK020572NIDDK NIH HHS P30 DK092926
6 · The paper itself

Abstract

backgroundStructural uncertainty can affect model-based economic simulation estimates and study conclusions. Unfortunately, unlike parameter uncertainty, relatively little is known about its magnitude of impact on life-years (LYs) and quality-adjusted life-years (QALYs) in modeling of diabetes. We leveraged the Mount Hood Diabetes Challenge Network, a biennial conference attended by international diabetes modeling groups, to assess structural uncertainty in simulating QALYs in type 2 diabetes simulation models.

methodsEleven type 2 diabetes simulation modeling groups participated in the 9th Mount Hood Diabetes Challenge. Modeling groups simulated 5 diabetes-related intervention profiles using predefined baseline characteristics and a standard utility value set for diabetes-related complications. LYs and QALYs were reported. Simulations were repeated using lower and upper limits of the 95% confidence intervals of utility inputs. Changes in LYs and QALYs from tested interventions were compared across models. Additional analyses were conducted postchallenge to investigate drivers of cross-model differences.

resultsSubstantial cross-model variability in incremental LYs and QALYs was observed, particularly for HbA1c and body mass index (BMI) intervention profiles. For a 0.5%-point permanent HbA1c reduction, LY gains ranged from 0.050 to 0.750. For a 1-unit permanent BMI reduction, incremental QALYs varied from a small decrease in QALYs (-0.024) to an increase of 0.203. Changes in utility values of health states had a much smaller impact (to the hundredth of a decimal place) on incremental QALYs. Microsimulation models were found to generate a mean of 3.41 more LYs than cohort simulation models (

conclusionsVariations in utility values contribute to a lesser extent than uncertainty captured as structural uncertainty. These findings reinforce the importance of assessing structural uncertainty thoroughly because the choice of model (or models) can influence study results, which can serve as evidence for resource allocation decisions.HighlightsThe findings indicate substantial cross-model variability in QALY predictions for a standardized set of simulation scenarios and is considerably larger than within model variability to alternative health state utility values (e.g., lower and upper limits of the 95% confidence intervals of utility inputs).There is a need to understand and assess structural uncertainty, as the choice of model to inform resource allocation decisions can matter more than the choice of health state utility values.

Indexed as

Diabetes Mellitus, Type 2Quality of LifeCost-Benefit AnalysisGlycated HemoglobinHumansModels, EconomicQuality-Adjusted Life YearsUncertaintyGlycated Hemoglobincross-model variabilitydiabeteseconomic modelquality-of-lifesimulation modelstructural uncertainty

Identifiers

PMID34911405
PMCPMC9329757

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.